VistaGen Therapeutics, Inc. Form SC 13G August 01, 2011

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No \_\_\_\_)

VistaGen Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.001 (Title of Class of Securities)

92840H103 (CUSIP Number)

May 11, 2011 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

" Ru	le 1	13d	-1	(b)	)

x Rule 13d-1(c)

<sup>&</sup>quot;Rule 13d-1(d)

# CUSIP No. 92840H103 (1) Names of Reporting Persons. Platinum Long Term Growth VII, LLC (2) Check the Appropriate Box if a Member of a Group (See Instructions). (a) " (b) " (3) SEC Use Only. (4) Citizenship or Place of Organization. Delaware (5) Sole Voting Power: 2,042,862 Number of Shares Beneficially (6) Shared Voting Power: 0 Owned by Each (7) Sole Dispositive Power: 2,042,862 Reporting Person With (8) Shared Dispositive Power: 0 (9) Aggregate Amount Beneficially Owned by Each Reporting Person. 2,042,862 shares of common stock. See Item 4. (10) Check if the Aggregate Amount in Row 9 Excludes Certain Shares. [X] See Item 4. (11) Percent of Class Represented by Amount in Row 9. 12.9% (12) Type of Reporting Person (See Instructions). 00

#### Item 1.

(a) Name of Issuer.

VistaGen Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices.

384 Oyster Point Blvd., No. 8 South San Francisco, CA 94080

Item 2.

- (a) Name of Person Filing.
- (b) Address or Principal Business Office or, if none, Residence.
- (c) Citizenship or Place of Organization.

Platinum Long Term Growth VII, LLC 152 West 57th Street, 4th Floor New York, NY 10019 State of Delaware

(d) Title of Class of Securities.

Common Stock, par value \$0.001 per share

(e) CUSIP No.

92840H103

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

- (a) "Broker or dealer registered under section 15 of the Act.
  (b) "Bank as defined in Section 3(a)(6) of the Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Act.
- (d) Investment company registered under section 8 of the Investment Company Act of 1940.

  (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) " A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h)  $\ddot{}$  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) "A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
  - (j) "Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

3

# Item 4. Ownership.

Platinum Long Term Growth VII, LLC

(a) Amount Beneficially Owned: 2,042,862 shares of common stock.

As of July 28, 2011, the number of shares beneficially owned includes 2,042,862 shares of common stock owned by the Reporting Person.

The number of shares beneficially owned excludes (i) 1,599,858 shares held by the Reporting Person that may be acquired upon the exercise of warrants, and (ii) 3,368,169 shares that may be acquired by the Reporting Person upon conversion of convertible notes. The warrants and convertible notes provide a limitation on the exercise of such warrants and notes, such that the number of shares of common stock that may be acquired by the holder upon exercise of the warrants or conversion of the notes is limited to the extent necessary to ensure that, following such exercise, the total number of shares of common stock then beneficially owned by the holder does not exceed 9.99% of the total number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such exercise or conversion) of the Issuer without providing the Issuer with 61 days' prior notice thereof. The formula for determining the number of shares of common stock that may be acquired by the holder upon conversion of the notes is subject to adjustment as a result of, among other factors, future offerings of the Issuer's securities and the number of the Issuer's shares of common stock on a modified fully-diluted basis.

The shares in this Schedule 13G are after giving effect to the 2-for-1 forward stock split by the Issuer effective on June 10, 2011.

- (b) Percent of class: 12.9%
- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote: 2,042,862
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 2,042,862
- (iv) Shared power to dispose or to direct the disposition of: 0

#### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ".

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

4

# Edgar Filing: VistaGen Therapeutics, Inc. - Form SC 13G

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. N/A

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 1, 2011

PLATINUM LONG TERM GROWTH VII, LLC

By: /s/ OLIVER JIMENEZ Oliver Jimenez Chief Compliance Officer

5